Did Eastern Capital Ltd increased Its Tapimmune Inc Position?

May 16, 2018 - By Alice Fox

TapImmune, Inc. (NASDAQ:TPIV) Corporate Logo

Eastern Capital Ltd reported increased Interest in Tapimmune Inc

By clicking the link 000140840818000005 you will find SC 13D/A SEC filling disclosed by Eastern Capital Ltd about Tapimmune Inc.The filler increased its holding in the stock by 24.53 % for 5,300,002 shares.Eastern Capital Ltd currently owns 38.8% of the stock. This ownership filing was filed because activity on May14, 2018.

And that’s Why Eastern Capital Ltd Holds Tapimmune Inc

Item 4.Purpose of Transaction

On May 14, 2018, Eastern CapitalLimited entered into a Common Stock Purchase Agreement with the Issuer to purchase 1,300,000 shares of common stock at a priceper share of $2.40.

The Reporting Persons acquiredthe Issuer’s securities for investment purposes.

The Reporting Persons currentlyhave no plans or proposals which relate to or would result in any transaction, event or action enumerated in paragraphs (a) through(j) of Item 4 of Schedule 13D.

CUSIP No. 876033408 Page 6 of 8

Ticker’s shares touched $3.26 during the last trading session after 7.59% change.TapImmune, Inc. has 153,209 shares volume, 262.58% up from normal. TPIV is downtrending and has moved 26.26% since May 17, 2017. TPIV underperformed by 37.81% the S&P500.

TapImmune, Inc., a clinical-stage immuno-oncology company, develops peptide and gene immunotherapeutics and vaccines for the treatment of cancer and metastatic disease.The firm is valued at $34.64 million. It specializes in the development of immunotherapies targeting women's cancers advancing multiple Phase II and Phase Ib/II clinical studies for the treatment of ovarian and breast cancers.Last it reported negative earnings. The company's peptide-or nucleic acid immunotherapeutic products comprise one or multiple naturally processed epitopes designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid expression systems.

For more TapImmune, Inc. (NASDAQ:TPIV) news posted recently go to: Prnewswire.com, Prnewswire.com, Benzinga.com, Prnewswire.com or Prnewswire.com. The titles are as follows: “TapImmune to Present at 2018 NYC Oncology Investor Conference” posted on May 07, 2018, “TapImmune Creates Scientific Advisory Board to Support Clinical Development of Multi-Antigen Cell Therapy Platform” on May 16, 2018, “32 Stocks Moving In Tuesday’s Mid-Day Session” with a publish date: May 01, 2018, “TapImmune and Marker Therapeutics Announce Entry into Merger Agreement, Creating a Transformational Immuno …” and the last “TapImmune to Host Investor Breakfast to Discuss Proposed Merger with Marker Therapeutics” with publication date: May 15, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.